A Milk Sugar and Probiotic Combo Relieved Constipation and Depression in Mice

Constipation and depression are more intertwined than most people realize. Up to a third of individuals with depression also experience chronic constipation, and studies in clinical populations suggest roughly one in four chronic constipation patients meets criteria for depression or anxiety. A new mouse study published in the Journal of Agricultural and Food Chemistry by Tian Z and colleagues now suggests that pairing a human milk oligosaccharide called 6'-sialyllactose (6'-SL) with the probiotic strain Bifidobacterium animalis subsp. lactis BB12 (BB12) could address both problems at once, by reshaping the gut microbiome and calming inflammation along the gut-brain axis. The research is early and conducted entirely in animals, so the findings are preliminary.

6'-Sialyllactose and BB12 Reverse Constipation Markers in Mice

The researchers induced constipation in mice using loperamide, the same compound found in common anti-diarrheal medications. Loperamide slows gut motility by binding opioid receptors in the intestinal wall, producing a reliable model of functional constipation. Animals treated with the 6'-SL and BB12 combination showed meaningful improvements across several bowel metrics: fecal water content rose, the number of fecal pellets increased, gastrointestinal transit rate improved, and the time to first black feces, a standard measure of gut speed, dropped. These are concrete, measurable signs that the intervention was moving the gut in the right direction.

The combination also modulated two proteins central to gut barrier function: AQP3, an aquaporin that governs water transport across intestinal membranes, and Claudin-1, a tight-junction protein that keeps the gut lining sealed. Additionally, key proteins in the SCF/c-Kit signaling pathway, which governs the pacemaker cells responsible for rhythmic intestinal contractions, were positively regulated. In plain terms, the synbiotic appeared to restore both the physical seal of the gut wall and its electrical rhythm.

Depression-like Behaviors Also Improved After Synbiotic Treatment

Loperamide did more than slow the bowels; it also pushed the mice toward depression-like behavior, consistent with what clinicians observe in human patients. After synbiotic treatment, those behavioral markers improved. The study authors trace the effect to two mechanisms operating in parallel: suppression of inflammatory signaling and modulation of synaptic plasticity proteins in the brain.

Inflammation is increasingly understood as a driver of mood disorders, and probiotics targeting the gut-brain axis have shown promise in preclinical depression research precisely because they can quiet immune activation in the gut before it reaches the brain. In this study, the 6'-SL and BB12 combination reduced those inflammatory signals while also affecting proteins involved in synaptic strength, the molecular infrastructure of mood regulation. Whether the gut changes drove the brain changes, or vice versa, the study does not fully resolve; the two processes likely reinforce each other.

This is not the first time 6'-SL has been linked to behavioral benefits. Earlier animal research found that 6'-sialyllactose prevented stress-induced shifts in gut microbial communities and reduced anxiety-like behavior in mice, suggesting a consistent theme around this prebiotic's effects on the gut-brain axis.

How the Synbiotic Reshaped the Gut Microbiome

The gut microbiome changes the team observed help explain both the bowel and the mood findings. Mice receiving the 6'-SL and BB12 combination showed increased overall microbial diversity, a feature broadly associated with gut resilience. At the level of specific taxa, the relative abundance of Bacteroidetes rose, as did the proportion of Akkermansia, a genus consistently linked to gut barrier integrity and metabolic health.

Elevated short-chain fatty acids (SCFAs) accompanied those microbial shifts. SCFAs, produced when gut bacteria ferment dietary fibers, serve multiple roles: they fuel colonocytes, regulate immune tone, and can cross into systemic circulation where they influence brain function. The rise in SCFAs here may help explain both the improved motility and the blunted inflammatory signaling observed in the behavioral tests.

For context, animal models have proven valuable in dissecting gut-brain axis mechanisms precisely because they allow researchers to control diet, microbiome history, and stress exposure in ways impossible in human trials, giving mechanistic clarity even when generalizability remains uncertain.

Open Questions Before Any Human Application

The study's limitations are significant and worth naming directly. Every measurement was made in loperamide-dosed mice, a specific and somewhat artificial model of constipation. Loperamide-induced constipation does not perfectly replicate the idiopathic chronic constipation most people experience, nor does the depression-like behavior it produces fully capture human mood disorders, which are heterogeneous and multifactorial.

More broadly, translating microbiota-gut-brain axis research from rodents to human clinical trials remains a substantial scientific challenge, with many promising animal results failing to replicate at scale in people. The dosing, the specific ratio of 6'-SL to BB12, and the duration of treatment that would be safe and effective in humans are all unknown.

What Comes Next for 6'-SL and BB12 as Functional Foods

The authors frame the results as groundwork for developing functional food products containing 6'-SL and BB12 as a synbiotic pair. 6'-SL is already approved as a food ingredient in several markets, and BB12 is one of the most studied commercial probiotic strains, so regulatory and safety profiles exist for both. That practical foundation means this combination could reach human trial phases faster than an entirely novel compound might.

The next step would be controlled human studies in people with functional constipation, ideally with validated depression or anxiety scales as secondary outcomes. If even a fraction of the gut microbiome and behavioral improvements seen in mice transfer to people, the combination would represent an accessible, food-based intervention for a pair of conditions that often resist treatment and frequently occur together. For now, the evidence is firmly in the preliminary column, but the mechanistic detail the team has assembled gives researchers a clear roadmap to follow.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• All data are from a mouse model of loperamide-induced constipation; results may not translate to humans.
• No human clinical trial data are available for this specific synbiotic combination.
• Funding source was not disclosed, limiting full assessment of potential conflicts of interest.

Mouse-only preclinical study using a loperamide-induced constipation model. Results demonstrate mechanistic associations between the synbiotic intervention and gut-brain axis markers but cannot establish causation in humans, and the findings have not yet been replicated in clinical populations.

References

1. Zihao Tian, Zhongmei Tan, Xuguang Zhang, et al. (2026). 6′-Sialyllactose Combined with Bifidobacterium animalis subsp. lactis BB12 Relieves Constipation and Depression-like Behaviors Induced by Loperamide in Mice by Regulating the Gut–Brain Axis. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/acs.jafc.5c17817
2. A Moody Gut Often Accompanies Depression—New Study Helps Explain Why. cuimc.columbia.edu. https://www.cuimc.columbia.edu/news/moody-gut-often-accompanies-depression-new-study-helps-explain-why
3. Psychological disorders in patients with chronic constipation – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985474/
4. Hui Wang, Yining Chen, Allen Zhao, Zhongxia Shen, Yu Zhang (2026). The role of probiotics in modulation of the gut-brain axis: a prospective therapy for depression and mood disorders. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1709060
5. Andrew J. Tarr, Jeffrey D. Galley, Sydney E. Fisher, Maciej Chichlowski, Brian M. Berg, Michael T. Bailey (2015). The prebiotics 3′Sialyllactose and 6′Sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: Evidence for effects on the gut–brain axis. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2015.06.025
6. Using Animal Models to Study the Role of the Gut–Brain Axis in Autism – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430852/
7. Sofia D. Forssten, Arthur C. Ouwehand, Síle M. Griffin, Elaine Patterson (2022). One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials. Nutrients. https://doi.org/10.3390/nu14030568